Cardiovascular risk in chronic kidney disease: what is new in the pathogenesis and treatment?

Postgrad Med 2018 Jun 12;130(5):461-469. Epub 2018 Jun 12.

a 2-nd Department of Nephrology and Hypertension with Dialysis Centre , Medical University of BiaƂystok , Bialystok , Poland.

The prevalence of chronic kidney disease (CKD) has increased markedly over past decades due to the aging of the worldwide population. Despite the progress in the prevention and treatment, the cardiovascular (CV) morbidity and mortality remain high among patients with CKD. Although CKD is a progressive and irreversible condition, it is possible to slow decreasing kidney function, as well as the development and progression of associated with kidney disease comorbidities. Diabetes mellitus has become major cause of CKD worldwide. It is estimated that the prevalence of diabetes will increase from 425 million worldwide in 2017 to 629 million by 2045, substantially the percentage of diabetic nephropathy among CKD patients is set to rise markedly. The results of multicenter trials concerning novel antidiabetic drugs suggest that efficacy in reducing CV risk is independent of the improvement in glycemic control. This review discusses underlying causes of high CV risk and strategies reducing individual burden among CKD patients.

Download full-text PDF

Source
http://dx.doi.org/10.1080/00325481.2018.1481714DOI Listing
June 2018
4 Reads

Publication Analysis

Top Keywords

kidney disease
12
ckd patients
8
chronic kidney
8
ckd
6
associated kidney
4
progression associated
4
risk independent
4
development progression
4
disease comorbidities
4
comorbidities diabetes
4
mellitus major
4
diabetes mellitus
4
ckd worldwide
4
major ckd
4
reducing risk
4
independent improvement
4
condition slow
4
multicenter trials
4
irreversible condition
4
progressive irreversible
4

References

(Supplied by CrossRef)

Dc W et al.
J Am Heart Assoc 2014

Similar Publications